Clinical trial · no report yet · Phase 3
ALBAN
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
- NCT03799835 ↗
- Active not recruiting
- UNICANCER
- 82 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 40 | |
| YouTube | 23 | |
| Podcasts | 19 |
The trial
ClinicalTrials.gov- Official title
- An Open Label, Randomized, Phase III Trial, Evaluating Efficacy of Atezolizumab in Addition to One Year BCG (Bacillus CaLmette-Guerin) Bladder Instillation in BCG-naive Patients With High-risk Non-muscle Invasive Bladder cANcer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Bladder Cancer
- Interventions
- BCG; Atezolizumab
- Arms
- Arm A : control arm · Active comparator
- Arm B: experimental arm · Experimental
- Enrollment
- 517
- Primary outcomes
- Event-Free Survival
- Sponsor
- UNICANCER with Hoffmann-La Roche
- Start
- Jan 17, 2019
- Primary completion
- Jun 2025 (estimated)
- Results posted
- No
- Registry record
- NCT03799835 · updated Dec 11, 2024